Average number of daily specimens collected prior to antimicrobial therapy was 33

Average number of daily specimens collected prior to antimicrobial therapy was 33.4 (range 3239) (n=10). As acquisition of abnormal vaginal flora has been associated with early menstrual cycle stages, sexual activity, and antecedent vaginal candidiasis [10,2124], we next analyzed our data for the presence of time-varying factors associated with compositional shifts of the vaginal microbiota. month after completion of therapy while the median time to this recurrence occurred only 14 days after treatment. == Conclusions == Our study demonstrates BV recalcitrance among HSV-2 infected women and provides additional evidence for a linkage between this chronic viral infection and abnormal vaginal flora. Additional work will be needed to define mechanisms responsible for this relationship and AT7867 2HCl to determine if vaginal flora health of HSV-2 infected women is improved by medications that suppress HSV-2 shedding. Keywords:bacterial vaginosis, herpes simplex virus type 2, metronidazole == Introduction == Bacterial vaginosis (BV) is a common genital tract condition dually characterized by reduced numbers of vaginal lactobacilli and overgrowth of facultative and anaerobic flora [1]. Although this re-proportioned microbiota composition can produce vaginal irritation and malodorous vaginal discharge, more frequently BV remains asymptomatic [2]. Reported associations with preterm delivery [3] and HIV acquisition [4,5] make BV a healthcare issue of considerable interest, but BV pathogenesis remains poorly understood. Also poorly understood are reasons why current antimicrobial therapies are so ineffective for prevention of BV recurrence. As example, while 1 week of oral metronidazole therapy, the most frequently prescribed therapy, achieved 1-month cure rates of ~ 85% [69], only a third of women responding to treatment maintained normal vaginal flora composition during the following year [10]. Taken together, the above observations suggest improved delineation of the mechanisms responsible for adverse clinical outcomes will better inform BV pathogenesis, and development of improved BV treatment strategies will benefit from better understanding of the risk factors promoting reduced numbers of vaginal lactobacilli and overgrowth of pathologic vaginal flora [11]. Two recent reports newly suggested that antecedent herpes simplex virus type 2 (HSV-2) infection represents an important risk factor for overgrowth of abnormal vaginal flora or reduced BV treatment efficacy [12,13]. Definitive evidence for causal connection between genital herpes infections and BV, however, is lacking as neither study determined HSV-2 genital tract shedding frequencies while both studies evaluated vaginal microbiota composition at infrequent 34 month intervals. Herein, we prospectively followed HSV-2 infected women with asymptomatic BV during the 1 month before and after completion of oral metronidazole therapy, asking each to collect daily vaginal swab specimens. These specimens were used to assess: 1) the relationship between vaginal flora composition and HSV-2 genital tract shedding; 2) BV persistence prior to antimicrobial therapy; and 3) BV recurrence rates subsequent to completion of this antimicrobial therapy. == Materials and Methods == == Study design == A pre- versus post-treatment study design was used to daily evaluate vaginal microbiota composition and HSV-2 shedding frequency among HSV-2 seropositive women with asymptomatic BV in the 1 month before and after oral metronidazole therapy AT7867 2HCl (study design approved by the University of Pittsburghs Institutional Review Board). AT7867 2HCl Nonpregnant women aged 1830 years presenting to 2 Pittsburgh, PA healthcare clinics (Magee-Womens Hospital and the Allegheny County Health Department Sexually Transmitted Disease Clinic) were screened for asymptomatic BV and HSV-2 infection. Women denying vaginal symptoms but who were diagnosed with asymptomatic BV (as defined by Amsel [14] and Nugent [15] criteria) and HSV-2 infection (as identified by point-of-care serologic tests [16]) were eligible. Exclusion criteria included pregnancy, current genital tract RECA infection withChlamydia trachomatis,Neisseria gonorrhoeae, orTrichomonas vaginalis; vaginal candidiasis; intrauterine device presence; spermicidal, antiviral, or antimicrobial agent usage in the 2 2 weeks prior to enrollment; or inability to tolerate systemic metronidazole therapy. Informed consent was obtained prior to enrollment, and a urine pregnancy test was AT7867 2HCl performed prior to specimen collection. Vaginal fluids were collected for determination of pH, amine (whiff) testing, microscopic analyses (wet preparation and Gram stain), and culture-basedT. vaginalisidentification. A Catch-All Sample Collection Swab (EPICENTRE Biotechnologies; Madison, WI) was applied to external and internal genitalia to detect HSV-2 DNA by real-time-PCR, and a AT7867 2HCl second swab placed endocervically for detection ofC. trachomatisandN. gonorrhoeaeby strand-displacement amplification. Women with currentT. vaginalis,C. trachomatis, orN. gonorrhoeaeinfection were excluded from study participation, and offered treatment in accordance with Centers for Disease Control and Prevention guidelines [17]. Enrolled participants were provided instructions and supplies for daily self-collection of genital tract swab specimens for HSV-2 detection and Gram stain diagnosis of BV. Each morning.